Hong Kong Patients Seek Dual-Targeted Cancer Drugs; United Family Pharmacist Explains New Therapies and International Standards
HK01 · 1 SOURCESabout 2 hours ago8 MIN
Summary
Hong Kong patients are increasingly looking to mainland China for cutting-edge dual-targeted cancer therapies. A pharmacist from United Family Healthcare's Shenzhen facility outlined how next-generation bispecific antibodies and antibody-drug conjugates (ADCs) are transforming oncology care, while emphasizing the importance of personalized treatment based on genetic testing. The hospital has implemented rigorous international-standard pharmaceutical management to address Hong Kong patients' concerns about drug authenticity and supply chain reliability.
Key Points
- Tumor treatment has evolved from traditional chemotherapy to single-target immunotherapy, now entering the era of bispecific antibodies that simultaneously target two cancer markers .
- China has achieved global breakthroughs with two world-first bispecific antibodies: a PD-1/VEGF antibody that restarts T-cell immunity and blocks tumor blood vessel formation, and a PD-L1/CTLA-4 antibody that解除s dual immune suppression .
- Clinical data presented at ASCO showed that the PD-1/VEGF antibody demonstrated significant improvements in overall survival and progression-free survival compared to traditional chemotherapy for lung cancer patients .
- The hospital has introduced subcutaneous injection formulations for dual-targeted therapy, reducing infusion time from several hours to approximately five minutes, significantly improving patient comfort .
- Known as "biological missiles," dual-targeted ADC drugs have shown objective response rates and progression-free survival times significantly doubled compared to traditional chemotherapy, with approved indications for late-stage nasopharyngeal cancer and potential in triple-negative breast cancer .
- Pharmacist Director Shi emphasized that innovative drugs are not "the newer the better" and that personalized treatment based on patient history, cancer type, and genetic testing biomarkers should be the primary principle .
- To address Hong Kong patients' concerns about mainland drug authenticity, the hospital sources all medications exclusively from top-tier suppliers with highest qualifications, ensuring full traceability .
- The pharmacy operates under international JCI standards with 24/7 electronic temperature and humidity monitoring, with real-time alerts and SMS notifications triggered if parameters exceed safe limits .
- Pharmacists have transitioned from traditional "dispensing" to proactive "clinical pharmacy management," providing comprehensive prescription evaluation, detailed medication education, drug interaction analysis, and active side effect management .
- Shenzhen-Hong Kong medical cooperation aims to achieve "seamless connection" through professional exchanges, data sharing, and enhanced patient education to help patients make informed treatment choices .
Why It Matters
The advancement of Greater Bay Area medical resource sharing is giving Hong Kong cancer patients access to mainland innovative drugs that are not yet available locally, expanding treatment options significantly . With strict international-standard pharmacy management and professional clinical pharmacist oversight, Hong Kong patients can now consider cross-border medical treatment with greater confidence and reduced concerns about drug quality and safety .
The advancement of Greater Bay Area medical resource sharing is giving Hong Kong cancer patients access to mainland innovative drugs that are not yet available locally, expanding treatment options significantly . With strict international-standard pharmacy management and professional clinical pharmacist oversight, Hong Kong patients can now consider cross-border medical treatment with greater confidence and reduced concerns about drug quality and safety .